Maruho Co., Ltd.

Quick facts

Marketed products

• Mitchga · Immunology
  Nemolizumab works by binding to the interleukin-31 receptor subunit alpha, blocking the action of interleukin-31 and reducing inflammation and itching.

Phase 3 pipeline

• CLS001 (Omiganan) · Infectious Disease / Dermatology
  Omiganan is an antimicrobial peptide that disrupts bacterial cell membranes by binding to lipopolysaccharides and lipoteichoic acids, leading to bacterial cell death.
• CLS006 · Dermatology
  CLS006 is a topical agent developed for dermatological conditions, likely targeting inflammatory or proliferative skin pathways.
• CLS006 Vehicle · Dermatology
  CLS006 Vehicle is a topical formulation vehicle designed to enhance drug delivery and penetration through the skin.
• M518101 · Dermatology
  M518101 is a topical agent developed for dermatological use, likely targeting inflammatory or proliferative skin conditions.
• Vehicle Topical Gel
  Vehicle Topical Gel is a topical formulation that serves as a vehicle for delivering active pharmaceutical ingredients.

Phase 2 pipeline

• CLS001
• CLS001 Topical Gel
• Digoxin Topical Gel
• Furosemide Topical Gel · Cardiovascular
  Furosemide acts as a loop diuretic by inhibiting the sodium-potassium-chloride cotransporter in the ascending limb of the loop of Henle.
• ICVT Topical Gel
• M516102

Phase 1 pipeline

• Omiganan 1% and Imiquimod
• Omiganan 2.5% and Imiquimod

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Maruho Co., Ltd. portfolio CI brief
• Maruho Co., Ltd. pipeline updates RSS